Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Characterization of ligand bias at the type 1 cannabinoid receptor

FY 2015-16

Summary
The type 1 cannabinoid receptor (CB1) regulates several processes, including pain perception, motor coordination, mood, reward, and appetite. CB1 is considered a major drug target for the treatment of pain, Huntington and Parkinson diseases, addiction, and obesity. Drugs (aka ligands) are usually thought of as compounds that selectively interact with a target in the body - for example, a receptor - to cause a specific effect. However, some drugs cause multiple effects because their receptors can act through multiple pathways within a cell. For example, delta9-tetrahydrocannabinol (THC), the major active drug in marijuana, may reduce pain by activating one set of proteins associated with CB1 and stimulate appetite by activating another set of proteins associated with CB1. A drug can be described as biased if it favours the activation of one set of proteins over another at the same receptor. This is known as ligand bias. A biased cannabinoid drug could selectively reduce pain without causing the other effects associated with CB1 activation, such as appetite stimulation, dizziness, and feelings of intoxication. The objective of my research project is to characterize CB1 ligand bias in order to develop safe and effective CB1-targetted drugs. CB1 ligand bias will be studied by testing a series of CB1-specific probe compounds in cell culture and animal behaviour experiments. These probe compounds permanently attach to specific parts of CB1 that may be important for ligand bias. Experiments with these probe compounds in cell culture will demonstrate which parts of CB1 are responsible for the differing effect cannabinoid drugs are known to have. Subsequent behavioural experiments in animals will then be used to demonstrate how the bias of a probe compound at the molecular level is shown in a living animal. From this research, biased ligands will be developed as effective CB1-targeted therapeutics.
Program
CIHR Fellowship
Location
Florida, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
338100
Name
Laprairie Robert B
Region
Florida
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of ligand bias at the type 1 cannabinoid receptor
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cannabinoid Receptor 1; Drug Discovery; G Protein-Coupled Receptor; Ligand Bias; Molecular Pharmacology
Abstract
The type 1 cannabinoid receptor (CB1) regulates several processes, including pain perception, motor coordination, mood, reward, and appetite. CB1 is considered a major drug target for the treatment of pain, Huntington and Parkinson diseases, addiction, and obesity. Drugs (aka ligands) are usually thought of as compounds that selectively interact with a target in the body - for example, a receptor - to cause a specific effect. However, some drugs cause multiple effects because their receptors can act through multiple pathways within a cell. For example, delta9-tetrahydrocannabinol (THC), the major active drug in marijuana, may reduce pain by activating one set of proteins associated with CB1 and stimulate appetite by activating another set of proteins associated with CB1. A drug can be described as biased if it favours the activation of one set of proteins over another at the same receptor. This is known as ligand bias. A biased cannabinoid drug could selectively reduce pain without causing the other effects associated with CB1 activation, such as appetite stimulation, dizziness, and feelings of intoxication. The objective of my research project is to characterize CB1 ligand bias in order to develop safe and effective CB1-targetted drugs. CB1 ligand bias will be studied by testing a series of CB1-specific probe compounds in cell culture and animal behaviour experiments. These probe compounds permanently attach to specific parts of CB1 that may be important for ligand bias. Experiments with these probe compounds in cell culture will demonstrate which parts of CB1 are responsible for the differing effect cannabinoid drugs are known to have. Subsequent behavioural experiments in animals will then be used to demonstrate how the bias of a probe compound at the molecular level is shown in a living animal. From this research, biased ligands will be developed as effective CB1-targeted therapeutics.
Competitiondate
201511
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Laprairie, Robert B
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~
Direct Payment - $100,000 Grant (2015-16) | Canada Spends